Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $9.1 million.

  • Eton Pharmaceuticals' Accumulated Expenses rose 1889375.0% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 1889375.0%. This contributed to the annual value of $8.9 million for FY2024, which is 6550.32% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Accumulated Expenses of $9.1 million as of Q3 2025, which was up 1889375.0% from $7.5 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Accumulated Expenses high stood at $11.4 million for Q2 2024, and its period low was $48000.0 during Q3 2024.
  • For the 5-year period, Eton Pharmaceuticals' Accumulated Expenses averaged around $4.7 million, with its median value being $4.9 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 9932.78% in 2024, then surged by 1889375.0% in 2025.
  • Eton Pharmaceuticals' Accumulated Expenses (Quarter) stood at $1.4 million in 2021, then soared by 168.08% to $3.7 million in 2022, then soared by 47.08% to $5.4 million in 2023, then skyrocketed by 65.5% to $8.9 million in 2024, then increased by 2.28% to $9.1 million in 2025.
  • Its Accumulated Expenses was $9.1 million in Q3 2025, compared to $7.5 million in Q2 2025 and $7.5 million in Q1 2025.